In CITYSCAPE, a phase II clinical trial, 135 patients with PD-L1 positive non-small-cell lung cancer were randomized to receive the TIGIT inhibitor tiragolumab in combination with a PD-L1 inhibitor or PD-L1 inhibitor alone. This evidence concerns the gene CD274 and non-small cell lung carcinoma.